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The increased circulation of norepinephrine, found in the diseased heart as a result of sympathetic nervous system overactivation, is
responsible for its cardiotoxic effects including pathological hypertrophy, cell death, and oxidative stress. Bucindolol is a third
generation adrenergic blocker, which acts on the β1 and β2 receptors, and has additional α1 antagonist activity. Thus, the aim
of this study was to investigate the action of bucindolol on oxidative stress, hypertrophy, cell survival, and cell death signaling
pathways in H9c2 cardiac cells exposed to norepinephrine. H9c2 cells were incubated with 10 μM norepinephrine for 24 h in
the presence or absence of bucindolol (10 μM) treatment for 8 h. Western blot was used to determine the expression of proteins
for hypertrophy/survival and death signaling pathways. Flow cytometry was used to assess cell death via caspase-3/7 activity and
propidium iodide and reactive oxygen species via measuring the fluorescence of CM-H2DCFDA. Norepinephrine exposure
resulted in an increase in oxidative stress as well as cell death. This was accompanied by an increased protein expression of
LC3B-II/I. The protein kinase B/mammalian target of the rapamycin (Akt/mTOR) pathway which is involved in cardiac
remodeling process was activated in response to norepinephrine and was mitigated by bucindolol. In conclusion, bucindolol was
able to modulate cardiac remodeling which is mediated by oxidative stress.
1. Introduction
Heart failure (HF) is a global pandemic, affecting nearly
26 million people worldwide [1]. Pathologic cardiac
remodeling in response to hemodynamic overload and
cardiac injury is associated with the activation of the
neuroendocrine system and an increase in oxidative stress
and inflammation eventually leading to cardiac dysfunc-
tion [2]. The activation of the neuroendocrine system
stimulates intracellular signaling pathways causing hyper-
trophy and fibrosis, activation of metalloproteinases, and
increase of oxidative stress leading to cell death by necro-
sis or apoptosis. This process is a key step in the devel-
opment of maladaptive hypertrophy, initiated by an
imbalance between proapoptotic and antiapoptotic pro-
teins [3]. Thus, the heart progresses from a compensatory
phase of adaptive hypertrophy to dilation with decreased
performance [4]. Therefore, blockage of the sympathetic
system has an important role in the attenuation of cardiac
remodeling in response to injury [5, 6]. Signal transducer
and activator of transcription 3 (STAT3) is an important
transcriptional factor that regulates cell proliferation, apo-
ptosis, and cardiac hypertrophy. Cardiac STAT3 levels are
dynamic and act as a sensor of both acute and chronic
stress to protect against oxidative damage or cell death
signaling [7].
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Despite the key beneficial role of autophagy in physio-
logic cardiac remodeling, excessive or insufficient autoph-
agy has been reported to contribute to adverse cardiac
remodeling [8]. Cardiac autophagy has been reported to
play an important role in response to increased norepineph-
rine levels [9]. Under nutrient-rich conditions, the phosphoi-
nositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian
target of rapamycin (mTOR) signaling cascade contributes to
inhibiting autophagy, whereas, under stress condition, inhi-
bition of mTOR caused by 5′ adenosine monophosphate-
activated protein kinase (AMPK) activates autophagy, caus-
ing the conversion of the microtubule-associated protein 1
light chain 3 (LC3-I) to LC3-II, essential for the formation
of autophagosomes [10].
Bucindolol is a nonselective β-adrenergic blocker (β1-
and β2-blocker) with vasodilatory properties by α1-antago-
nism [11] and mild sympatholytic effects [12]. We have pre-
viously demonstrated that bucindolol treatment improved
right ventricle (RV) systolic function; reduced RV pleomor-
phism, necrosis, and fibrosis; decreased infiltration of inflam-
matory cells; and decreased the sympathetic drive and
balance and myocardial burden in rats with pulmonary arte-
rial hypertension induced by monocrotaline [13]. Further-
more, bucindolol has also been reported to improve left
ventricular systolic and diastolic function in humans [14].
Despite evidence showing cardiovascular benefits of
bucindolol, its exact role in cardiac remodeling is still not
fully known. In the current study, we explored the role of
bucindolol in the signaling for hypertrophy/cell survival
and apoptosis pathways in H9c2 cardiac cells exposed to
norepinephrine.
2. Materials and Methods
2.1. Cell Culture. Rat cardiac cells (H9c2) (American Type
Culture Collection, Manassas, VA, USA) were cultivated in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10%
(v/v) Fetal Bovine Serum (FBS) (HyClone Laboratories,
Pittsburgh, PA, USA) and 1% antibiotic-antimycotic (100X)
(10,000U/ml of penicillin, streptomycin 10,000 μg/ml of
streptomycin, and 25μg/ml of Gibco amphotericin B)
(Gibco/Life Technologies, Carlsbad, CA, USA) and
incubated at 37°C with 5% CO2 and 100% humidity. To
maintain the cell culture, medium was changed every 2
to 3 days and cells were passaged when they reached 75-
80% confluence. Cells were seeded at 1 × 104 cells/well
for the MTT assay, 1 × 105 cells/ml for analysis on the flow
cytometry, and 1 × 106 cells/T-75 flask for Western blotting.
2.2. Treatment Conditions. Four treatment conditions were
established: (1) H9c2 cells that were not exposed to norepi-
nephrine or bucindolol (CTL), (2) H9c2 cells exposed to nor-
epinephrine (NE), (3) H9c2 cells incubated with bucindolol
(CTL+BCD), and (4) H9c2 cells exposed to norepinephrine
and bucindolol treatment (NE+BCD). The concentration of
norepinephrine was determined by the MTT cell viability
assay, where H9c2 cells were incubated with different con-
centrations of norepinephrine (2, 5, and 10 μM) at two
different time points (24 and 36 h). Based on the results,
10μM of norepinephrine for 24h was used for subsequent
experiments. Norepinephrine (Sigma-Aldrich, St. Louis,
MO, USA) was diluted in 0.5M HCl (0.03%), and incubation
was done in FBS- and antibiotic-antimycotic-free culture
medium. Subsequently, H9c2 cells were treated for 8 h with
bucindolol (10 μM) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), prepared in 0.01% DMSO (Dimethyl Sulfoxide;
Fisher Scientific, Ottawa, ON, CA).
2.3. Protein Expression.Western blot was used to analyze the
protein expression of different signaling proteins. H9c2
cells were lysed in PathScan lysis buffer (25mmol/l Tris
pH = 7 5, 150mmol/l NaCl, 1mmol/l EDTA, 1% Triton-X
100), sodium fluoride, sodium orthovanadate, and protease
inhibitors cocktail (Sigma-Aldrich, St. Louis, MO, USA),
using the Qiagen Tissue Lyser. Samples were centrifuged at
8000 g for 10 minutes at 4°C and supernatants were collected,
and the protein concentration was quantified using the DC
protein assay kit (Bio-Rad Laboratories, Mississauga, ON,
CA). Thirty micrograms of protein sample was subjected
to SDS-page gel electrophoresis (7–15% according to the
size of the proteins of interest) and electrophoretically
transferred to a nitrocellulose membrane using a Trans-
Blot apparatus (Bio-Rad Laboratories, Mississauga, ON,
CA). The membrane was blocked with 5% nonfat milk
in Tris-buffered saline (20mM Tris, 137mM NaCl) for
1 h at room temperature and then incubated overnight at
4°C with the following primary antibodies: 4-HNE
(1 : 500); phospho-Akt (1 : 2000), #4060S; Akt (1 : 250),
#9272; phospho-AMPKα (1 : 1000), #5256; AMPKα
(1 : 250), #2603; phospho-mTOR (1 : 1000), #2971; mTOR
(1 : 1000), #4517; LC3B-I/II (1 : 500), #2775; p70 S6 kinase
(1 : 1000), #9202; PI3 kinase p85-α (pTyr607) (1 : 500);
phospho-STAT3 (1 : 1000), #4113; and STAT3 (1 : 1000),
#12640. All antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA), except 4-HNE (ab46545;
Abcam, Cambridge, MA, USA) and PI3K (ABS234; Milli-
pore, Bedford, MA, USA). The bound primary antibodies
were detected with anti-rabbit or anti-mouse horseradish
peroxidase-conjugated secondary antibodies (1 : 1000–
1 : 5000) and were normalized to β-actin (sc-47778; Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Chemilumi-
nescence reaction was detected by the ChemiDoc XRS
System, supported by Quantity One software version
4.6.5 (Bio-Rad Laboratories, Mississauga, ON, CA), which
was analyzed by ImageJ software (Wayne Rasband,
Research Services Branch, NIH, Bethesda, MD, USA).
2.4. Cell Death Assays. Apoptosis of H9c2 cells was measured
by the presence of active caspase-3/7, detected by flow
cytometry (FACSCalibur Flow Cytometer; BD Biosciences,
San Jose, CA, USA) using the CaspaTag Caspase-3/7 In Situ
Assay Kit (Chemicon International, Temecula, CA, USA),
according to the manufacturer’s instructions. Active cas-
pase-3/7 positive cells were assessed on the basis of the
fluorescence after incubation with Fluorochrome Inhibitors
of Caspases (FLICA) reagent [15]. 10,000 events were
acquired per trial, and the data were expressed as
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fluorescence intensity in the M2 area of the histogram. The
activity of caspase-3/7 was expressed as the mean fluores-
cence intensity.
Necrosis was assessed via flow cytometric analysis of
H9c2 cells incubated with propidium iodide (PI) solution
(250 μg/ml) (Millipore, Bedford, MA, USA) for 10min. PI
is membrane impermeable in live cells but binds to DNA of
dead cells due to loss of cell membrane integrity, causing
increase in the fluorescence. For the analysis, the percentage
of PI positive cells was determined using a FACSCalibur
Flow Cytometer (BD Biosciences, San Jose, CA, USA)
(10,000 events) [16].
2.5. Reactive Oxygen Species (ROS) Assay. Intracellular
reactive oxygen species (ROS) level was assessed by incubat-
ing H9c2 cells with CM-H2DCFDA (5-[and-6]-chloro-
methyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl
ester) (Molecular Probes; Invitrogen, Carlsbad, CA, USA)
for 30min. After this incubation period, the dye solution
was removed by aspiration, and the cells were trypsinized
and centrifuged at 500×g for 5 minutes at 4°C. The samples
were analyzed by flow cytometry. To analyze the quantity
of ROS produced, we measured the fluorescence of CM-
H2DCFDA at 488 nm on the FL1 channel of a BD FACSCa-
libur Flow Cytometer (BD Biosciences) supported by BD
CellQuest Pro Software (BD Biosciences, San Jose, CA,
USA) [15]. Fluorescence was expressed as mean fluorescence,
after 10,000 events were acquired per trial.
2.6. Statistical Analysis. All statistical analyses were
performed using SigmaPlot software (Version 12.0, Systat
Software Inc., San Jose, USA). Normality was assessed using
the Shapiro-Wilk test. Comparisons between groups were
performed by two-way ANOVA, with a Tukey post hoc test.
Differences between groups were considered statistically
significant when P < 0 05.
3. Results
3.1. Signaling Protein Expression. To analyze the hypertrophy
and cell survival signaling pathways, the immunoblot of the
proteins STAT3, PI3K, Akt, mTOR, p70 S6K, and AMPK
was performed. With regard to the transcription factor
STAT3, there was a marked increase (32%) in its activity in
the NE condition compared to CTL (Figure 1(a)). Bucindolol
was effective in attenuating (39%) this increase in the NE+
BCD condition. The activity of the protein kinases PI3K
(Figure 1(b)) and Akt (Figure 1(c)) was found to be signifi-
cantly increased (73% and 56%, respectively) in the NE
condition in comparison to the CTL condition. Bucindolol
was efficient in mitigating this increase, as NE+BCD demon-
strated a 27% decrease in the PI3K expression and 38%
decrease in Akt activity when compared to the NE condition.
Moreover, there was an increase in mTOR activity (30%)
in the NE condition as compared to the CTL condition,
and bucindolol treatment did not alter mTOR activity
(Figure 1(d)). However, the p70 S6 kinase (p70 S6K) expres-
sion was significantly higher (123%) in the NE condition
when compared to the CTL condition, and the NE+BCD
condition showed a decrease (32%) in the p70 S6K level in
relation to the NE condition (Figure 1(e)). Similarly, we found










































Figure 1: Western blot of proteins involved in cell survival and cell death signaling pathway. H9c2 cardiac cells were incubated with
norepinephrine (10 μM) during a period of 24 h, followed by 8 h of bucindolol (10 μM) treatment. β-Actin was used for normalization.
Immunoblot of p-STAT3/total-STAT3 (a), PI3K (b), p-Akt/total Akt (c), p-mTOR/mTOR (d), p70 S6K (e), p-AMPK/total AMPK (f), and
LC3-II/LC3-I (g) was determined. Values were expressed as mean ± SD from 4 independent experiments. Two-way ANOVA followed
by Tukey test: AP < 0 05 vs. Control Untreated (CTL), BP < 0 05 vs. Norepinephrine Untreated (NE), CP < 0 05 vs. Control+Bucindolol
(CTL+BCD), +P < 0 05 CTL and CTL+BCD vs. NE and Norepinephrine+Bucindolol (NE+BCD), and ∗P < 0 05 CTL+BCD and NE+BCD
vs. CTL and NE.




















































































































5Oxidative Medicine and Cellular Longevity
compared to the CTL condition (Figure 1(f)). Moreover,
NE+BCD demonstrated a reduction of 48% in AMPK
activity in relation to the NE condition.
The LC3-II/I ratio which reflects the autophagic activity
was significantly upregulated in norepinephrine conditions
(NE and NE+BCD) as compared to control conditions
(CTL and CTL+BCD). Furthermore, the NE+BCD condition
showed an increase of 35% in this ratio when compared to
the NE condition (Figure 1(g)).
3.2. Cell Death. Cell death was assessed by measuring
caspase3/7 activity and by PI staining. A significant
increase in active caspase-3/7, a direct indicator of apopto-
sis, was evident in the NE condition in comparison to the
CTL condition. Bucindolol was able to reduce (66%) this
activity in the NE+BCD condition when compared to the
NE condition (Figures 2(a) and 2(b)). In relation to PI
staining, no significant differences were found between
CTL and NE conditions. However, NE+BCD decreased
(60%) the PI uptake when compared to the NE condition
(Figures 3(a) and 3(b)).
3.3. Oxidative Stress. Intracellular ROS measured by the
DCFH-DA assay are shown in Figures 4(a) and 4(b). No sig-
nificant difference in oxidative stress was observed between
CTL and NE conditions. However, the NE+BCD condition
demonstrated a significant reduction (34%) of the ROS in
relation to the NE condition.
Furthermore, bucindolol was effective in mitigating the
increase in lipid peroxidation caused by norepinephrine, as
the NE condition showed an increase (44%) in the 4-HNE
expression when compared to the CTL condition and the
NE+BCD condition demonstrated a decrease (20%) in the
protein expression in relation to the NE condition (Figure 5).
4. Discussion
In the present study, we have demonstrated that bucindolol, a
nonselective β-blocker/sympatholytic agent, modulated car-
diac remodeling by attenuating the signaling for apoptosis
in an in vitromodel of norepinephrine-induced cardiac dam-
age, and this was associated with reduced oxidative stress.
Chronic stress results in prolonged cardiac exposure to
norepinephrine, which through the activation of the α- and
β-adrenergic receptors induces changes in cardiac function
and structure, such as hypertrophy, which is an initial step
of cardiac remodeling and eventually triggering cell death
which represents the initial stage of heart failure [17]. Thus,
the in vitro model of norepinephrine-stimulated cardiomyo-
cytes is relevant and appropriate for assessing the cardiopro-
tective potential of drugs against damage caused by the
overactivation of the sympathetic nervous system [18].
Based on cell viability data (not shown), we chose
10 μM norepinephrine for 24 h in the presence and
absence of 10μM of bucindolol for 8 hours to investigate
the effect of bucindolol on markers of apoptosis, cell survival,
and oxidative stress.
The activation of adrenergic receptor induced by nor-
epinephrine is a primary mediator of cardiac hypertrophy.
STAT3 is an important transcription factor that regulates
cell differentiation, proliferation, and apoptosis [19] and is
known to be directly activated in cardiomyocytes by β-
adrenergic agonists [20]. Kishore and Verma have reported
that STAT3 signaling is activated during physiological
hypertrophy and inhibited under chronic pathological con-
ditions [21]. Other studies have demonstrated that persis-
tent STAT3 activation promotes uncontrolled growth and
survival through altered gene expression [22], leading to























Figure 2: Active caspase 3/7 was determined in H9c2 cardiac cells incubated with norepinephrine (10 μM) during a period of 24 h, followed
by 8 h of bucindolol (10 μM) treatment (c). Representative dot plots indicating the cell populations of all groups (a). Representative histogram
showing FL1-H fluorescence versus cell counts, indicating activated caspase-3/7 (M2 area) (b). Values expressed as mean ± SD from 3
independent experiments. Two-way ANOVA followed by Tukey: AP < 0 05 vs. Control Untreated (CTL), BP < 0 05 vs. Norepinephrine
Untreated (NE), +P < 0 05 CTL and Control+Bucindolol (CTL+BCD) vs. NE and Norepinephrine+Bucindolol (NE+BCD), and ∗P < 0 05
CTL+BCD and NE+BCD vs. CTL and NE.
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an increase in STAT3 activity in the NE condition, which
was reversed in the NE+BCD condition by bucindolol
treatment. Our study is the first to report that bucindolol
decreases STAT3 activity. The adrenergic receptor-induced
cardiac hypertrophy response usually involves the activation





































































































Figure 3: Cell death analysis by propidium iodide (PI) staining in H9c2 cardiac cells treated with norepinephrine (10 μM) for 24 h, followed
by 8 h of bucindolol (10 μM). PI shows the percent of dead cells (c). Representative dot plots indicating the cell populations of all groups (a).
Representative histogram indicating FL-2 fluorescence versus cell counts shown in (b). Values expressed asmean ± SD from 3-4 independent
experiments (b). Two-way ANOVA followed by Tukey: BP < 0 05 vs. Norepinephrine Untreated (NE), ∗P < 0 05 Control+Bucindolol
(CTL+BCD) and Norepineprine+Bucindolol (NE+BCD) vs. CTL and NE.
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pathway. The action of norepinephrine on the α-adrenergic
receptor in the heart results in the activation of phospho-
lipase C and formation of inositol triphosphate (IP3) and
1,2-diacylglycerol (DAG). Subsequently, DAG stimulates
cytosolic protein kinases activity, resulting in increased
protein synthesis and development of hypertrophy [23].
Through this signaling cascade, PI3K is activated, leading
to recruitment and activation of Akt. PI3K/Akt signaling is
essential for conferring cardioprotection in response to stim-
uli and it activates STAT3. Phosphorylated STAT3 is linked
to the activation of Akt, and this pathway is involved in cell
proliferation and cell growth. Numerous Akt targets are
involved in cardiac remodeling, including mTOR. When
activated by Akt, mTOR phosphorylates p70 S6K, which
plays a key role in the stimulation of protein synthesis in
the heart [24]. It is known that the activity of these pathways
is involved in the progression of cardiac hypertrophy to heart
failure [25]. In our study, we found an increase in the activity
of PI3K, Akt, and mTOR in the NE condition, as well as an
increased expression of the p70 S6K. Thus, our results sug-
gest cardiac hypertrophy in the NE condition. Bucindolol


































































































Figure 4: Oxidative stress analysis in H9c2 cardiac cells incubated with norepinephrine (10 μM) for 24 hours, followed by 8 hours of
bucindolol (10 μM) treatment. ROS was determined by the CM-H2DCFDA assay and measured by flow cytometry (c). Representative dot
plots indicating the cell populations of all groups (a). Representative histogram indicating cell counts of ROS levels versus FL1-H
fluorescence (b). Values expressed as mean ± SD from 3 independent experiments. Two-way ANOVA followed by Tukey: BP < 0 05 vs.
Norepinephrine Untreated (NE), ∗P < 0 05 Control+Bucindolol (CTL+BCD) and Norepineprine+Bucindolol (NE+BCD) vs. Control
Untreated (CTL) and NE.
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expression of these hypertrophy markers. Similarly,
Pönicke et al. have reported that in rat ventricular cardio-
myocytes, 10 μM of bucindolol inhibited noradrenaline-
induced protein synthesis [26].
The PI3K/Akt/mTOR signaling pathway has an impor-
tant role in regulating proliferation, cell growth, and
transcription of genes related to antioxidants, apoptosis,
and autophagy [25]. Cardiac autophagy plays an important
in the turnover of damaged macromolecules and organelles,
which is a key in maintaining cellular homeostasis [10].
Excessive autophagy is observed in the damaged cells, which
may be a trigger for cardiac apoptosis. During autophagy,
damaged organelles and proteins are degraded in the autoly-
sosome [10, 27]. Autophagy is initiated by phosphorylation
of AMPK, which inhibits mTOR [27]. This signaling
pathway leads to the conversion of the cytosolic precursor
LC3-I into LC3-II, which is essential for membrane exten-
sion, curvature, and closure of autophagosomes [10, 27]. In
our study, the NE condition demonstrated upregulation of
the AMPK/mTOR pathway and increased LC3-II/LC3-I
ratio. Previous studies have reported that STAT3 inhibited
autophagy via inhibition of oxidative stress [28]. Xu et al. also
demonstrated a significant increase in AMPK activity in
norepinephrine-treated H9c2 cells, caused by the stimulation
of α1-adrenergic receptor [29]. In the NE+BCD condition,
we observed an increase in mTOR activity and LC3-
II/LC3-I ratio. Recent literature suggests that the persistent
adrenergic hyperstimulation that triggers autophagy in
cardiac cells could contribute to reducing the deleterious
effects of norepinephrine, acting as a cardioprotective
response against apoptosis [9, 30].
While limited adrenergic stimulation causes myocyte
hypertrophy, adrenergic overdrive contributes to myocyte
loss because of altered antiapoptotic Bcl-2 protein expres-
sion. Activation of the β2 receptor is responsible for the
antiapoptotic action [6]. It is known that cardiomyocytes
predominantly express β1, and thus, the hyperactivation
of these receptors has an important role not only in
ventricular remodeling but also in inducing apoptosis
[31, 32]. It is known that the imbalance between Bax/Bcl-2
is responsible in changing the mitochondrial membrane
potential, generating the opening of mitochondrial mem-
brane pores, with subsequent activation of the caspases
[14, 15]. A significant increase of the activation of effector
caspases-3/7 was evident in the NE condition in relation
to CTL and NE+BCD conditions. In healthy cells, the cas-
pases reside in the cytosol and its activation is achieved by
autoactivation, transactivation, or proteolysis [33]. We
have demonstrated that norepinephrine results in apopto-
sis and bucindolol has antiapoptotic action, as the activa-
tion of the caspases-3/7 is its final target. To confirm the
cardioprotective role of bucindolol in cell death pathways,
PI assessment was performed. Bucindolol significantly
reduced the number of dead cells in the NE+BCD condi-
tion compared to the NE condition.
A recent study reported that different concentrations of
NE lead to either hypertrophic or apoptotic response which
is associated with distinct pattern of ROS production [34].
Moreover, Saleem and Goswami demonstrated that the acti-
vation of cardiac adrenergic receptors by norepinephrine
costimulated the generation of Nox2, leading to the produc-
tion of superoxide anion [35]. Increase in oxidative stress
leads to lipid peroxidation, which modify cell integrity
through altering cell permeability [36]. 4-HNE is the stable
by-product of lipid peroxidation causing changes in cell
signaling, DNA damage, and inducing apoptosis by the
activation of the caspases [37]. Moreover, the PI3K-
mediated cell survival pathway is known to protect against
4-HNE-mediated oxidative damage [38].
Although we did not observe a significant increase in
ROS levels in the NE-exposed cells as measured by CM-
H2DCFDA (which is a general indicator of oxidative stress),
there was a significant increase in the protein expression of
4-HNE (a more specific marker of oxidative stress) suggest-
ing that NE may lead to a distinct repertoire of ROS depend-
ing on the dose and exposure time as suggested by a recent
study by Thakur et al. [34]. Bucindolol was able to attenuate
oxidative stress in the NE+BCD condition, suggesting that
bucindolol may possess antioxidant potential.
This study has certain limitations. These experiments
were performed with H9c2 cardiac cells which is a commonly
used cell line for the in vitro studies. Thus, our observations
cannot be fully extrapolated to the in vivo conditions. How-
ever, H9c2 cells have also been used previously by other
investigators to study the cardiac effects of norepinephrine










































Figure 5: Lipid peroxidation measured by determination of
relative protein levels of 4-hydroxynonenal (4-HNE) adducts in
H9C2 cardiac cells incubated with norepinephrine (10 μM) for
24 h, followed by 8 h of bucindolol (10 μM) treatment. β-Actin
was used for normalization. Values expressed as mean ± SD
from 3-4 independent experiments. Two-way ANOVA followed
by Tukey: AP < 0 05 vs. Control Untreated (CTL), BP < 0 05 vs.
Norepinephrine Untreated (NE), +P < 0 05 CTL and Control+
Bucindolol (CTL+BCD) vs. NE and Norepinephrine+Bucindolol
(NE+BCD).
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the protein expression of LC3B-I and LC3B-II to assess
autophagy. Employing other techniques to measure autoph-
agy flux would have been ideal.
5. Conclusion
Bucindolol treatment was able to prevent the increase in
cardiac hypertrophy signaling and apoptosis, a characteristic
of heart diseases due to sympathetic hyperactivity. The bene-
ficial effects of bucindolol appeared to be due to the modula-
tion of ROS generation and oxidative damage (Figure 6).
Data Availability
The data used to support the findings of this study are
included within the article.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contributions
Data collection, analysis, and writing the first draft were done
by Lima-Seolin BG de. Khaper N and Belló-Klein A designed
the study and supervised the research. Flow cytometry data
acquisition was done by Lima-Seolin BG de, Nemec-Bakk
A, Forstyth H, and Kirk S. Critical revision of the manuscript
was done by Araujo AS, Schenkel PC, Belló-Klein A, and
Khaper N. Khaper N was the primary investigator.
Acknowledgments
This work was funded by the Brazilian Research Agencies:
Coordenação de Aperfeiçoamento de Pessoal de Nível
Superior (CAPES)–Program CAPES/DFADT and Conselho
Nacional de Desenvolvimento Científico e Tecnológico
(CNPq), as well as the Northern Ontario School of Medicine
(NOSM) Faculty Association Research Development Funds.
References
[1] G. Savarese and L. H. Lund, “Global public health burden of
heart failure,” Cardiac Failure Review, vol. 3, no. 1, pp. 7–11,
2017.
[2] M. Chiong, Z. V. Wang, Z. Pedrozo et al., “Cardiomyocyte
death: mechanisms and translational implications,” Cell Death
& Disease, vol. 2, no. 12, p. e244, 2011.
[3] J. E. Chipuk, T. Moldoveanu, F. Llambi, M. J. Parsons, and
D. R. Green, “The BCL-2 family reunion,” Molecular Cell,
vol. 37, no. 3, pp. 299–310, 2010.
[4] H. Zhu, P. Tannous, J. L. Johnstone et al., “Cardiac autoph-
agy is a maladaptive response to hemodynamic stress,” The
Journal of Clinical Investigation, vol. 117, no. 7, pp. 1782–
1793, 2007.
[5] C. Communal and W. S. Colucci, “The control of cardiomyo-
cyte apoptosis via the beta-adrenergic signaling pathways,”
Archives des Maladies du Coeur et des Vaisseaux, vol. 98,
no. 3, pp. 236–241, 2005.
[6] S.-Y. Shin, T. Kim, H.-S. Lee et al., “The switching role of
β-adrenergic receptor signalling in cell survival or death
decision of cardiomyocytes,” Nature Communications,
vol. 5, no. 1, article 5777, 2014.
[7] A. Haghikia, B. Stapel, M. Hoch, and D. Hilfiker-Kleiner,
“STAT3 and cardiac remodeling,” Heart Failure Reviews,
vol. 16, no. 1, pp. 35–47, 2011.
[8] D. Glick, S. Barth, and K. F. Macleod, “Autophagy: cellular and
molecular mechanisms,” The Journal of Pathology, vol. 221,
no. 1, pp. 3–12, 2010.
[9] M. Nakaoka, E. Iwai-Kanai, M. Katamura, Y. Okawa, Y. Mita,
and S. Matoba, “An alpha-adrenergic agonist protects hearts
by inducing Akt1-mediated autophagy,” Biochemical and
Biophysical Research Communications, vol. 456, no. 1,
pp. 250–256, 2015.
[10] C. He and D. J. Klionsky, “Regulation mechanisms and signal-
ing pathways of autophagy,” Annual Review of Genetics,
vol. 43, no. 1, pp. 67–93, 2009.
[11] M. R. Bristow, “β-Adrenergic receptor blockade in chronic
heart failure,” Circulation, vol. 101, no. 5, pp. 558–569, 2000.
[12] M. R. Bristow, G. A. Murphy, H. Krause-Steinrauf et al.,
“An α2C-adrenergic receptor polymorphism alters the
norepinephrine-lowering effects and therapeutic response
of the β-blocker bucindolol in chronic heart failure,” Circu-
lation: Heart Failure, vol. 3, no. 1, pp. 21–28, 2010.
[13] B. G. de Lima-Seolin, R. Colombo, J. H. P. Bonetto et al.,
“Bucindolol improves right ventricle function in rats with
pulmonary arterial hypertension through the reversal of
autonomic imbalance,” European Journal of Pharmacology,
vol. 798, pp. 57–65, 2016.
[14] E. J. Eichhorn, J. B. Bedotto, C. R. Malloy et al., “Effect of beta-
adrenergic blockade on myocardial function and energetics in
congestive heart failure. Improvements in hemodynamic, con-
tractile, and diastolic performance with bucindolol,” Circula-
tion, vol. 82, no. 2, pp. 473–483, 1990.
[15] S. Bryan, G. Yang, R. Wang, and N. Khaper, “Cystathionine
gamma-lyase-deficient smooth muscle cells exhibit redox
imbalance and apoptosis under hypoxic stress conditions,”
Experimental and Clinical Cardiology, vol. 16, no. 4, pp. e36–
e41, 2011.
[16] E. A. I. F. Queiroz, S. Puukila, R. Eichler et al., “Metformin










Figure 6: Bucindolol modulates norepinephrine-induced cardiac
remodeling by attenuating oxidative stress and cell death.
10 Oxidative Medicine and Cellular Longevity
stress, AMPK and FOXO3a in MCF-7 breast cancer cells,”
PLoS One, vol. 9, no. 5, article e98207, 2014.
[17] C. Schroeder and J. Jordan, “Norepinephrine transporter
function and human cardiovascular disease,” American Jour-
nal of Physiology. Heart and Circulatory Physiology, vol. 303,
no. 11, pp. H1273–H1282, 2012.
[18] X. L. Louis, S. J. Thandapilly, W. Kalt et al., “Blueberry
polyphenols prevent cardiomyocyte death by preventing
calpain activation and oxidative stress,” Food & Function,
vol. 5, no. 8, pp. 1785–1794, 2014.
[19] P. Fischer and D. Hilfiker-Kleiner, “Survival pathways in
hypertrophy and heart failure: the gp130-STAT3 axis,” Basic
Research in Cardiology, vol. 102, no. 5, pp. 393–411, 2007.
[20] W. Zhang, X. Qu, B. Chen et al., “Critical roles of STAT3 in β-
adrenergic functions in the heart,” Circulation, vol. 133, no. 1,
pp. 48–61, 2016.
[21] R. Kishore and S. K. Verma, “Roles of STATs signaling in car-
diovascular diseases,” JAK-STAT, vol. 1, no. 2, pp. 118–124,
2012.
[22] J. Turkson, “STAT proteins as novel targets for cancer drug
discovery,” Expert Opinion on Therapeutic Targets, vol. 8,
no. 5, pp. 409–422, 2004.
[23] Y. E. G. Eskildsen-Helmond, K. Bezstarosti, D. H. W. Dekkers,
H. A. A. van Heugten, and J. M. J. Lamers, “Cross-talk between
receptor-mediated phospholipase C-β and D via protein
kinase C as intracellular signal possibly leading to hypertrophy
in serum-free cultured cardiomyocytes,” Journal of Molecular
and Cellular Cardiology, vol. 29, no. 9, pp. 2545–2559, 1997.
[24] J. R. McMullen, T. Shioi, L. Zhang et al., “Deletion of ribo-
somal S6 kinases does not attenuate pathological, physiologi-
cal, or insulin-like growth factor 1 receptor-phosphoinositide
3-kinase-induced cardiac hypertrophy,” Molecular and Cellu-
lar Biology, vol. 24, no. 14, pp. 6231–6240, 2004.
[25] T. Aoyagi and T. Matsui, “Phosphoinositide-3 kinase signaling
in cardiac hypertrophy and heart failure,” Current Pharmaceu-
tical Design, vol. 17, no. 18, pp. 1818–1824, 2011.
[26] K. Pönicke, I. Heinroth-Hoffmann, and O.-E. Brodde, “Differ-
ential effects of bucindolol and carvedilol on noradenaline-
induced hypertrophic response in ventricular cardiomyocytes
of adult rats,” The Journal of Pharmacology and Experimental
Therapeutics, vol. 301, no. 1, pp. 71–76, 2002.
[27] C. H. Jung, S. H. Ro, J. Cao, N. M. Otto, and D. H. Kim,
“MTOR regulation of autophagy,” FEBS Letters, vol. 584,
no. 7, pp. 1287–1295, 2010.
[28] L. You, Z. Wang, H. Li et al., “The role of STAT3 in autoph-
agy,” Autophagy, vol. 11, no. 5, pp. 729–739, 2015.
[29] M. Xu, Y. T. Zhao, Y. Song et al., “Alpha1-adrenergic receptors
activate AMP- activated protein kinase in rat hearts,” Sheng Li
Xue Bao, vol. 59, no. 2, pp. 175–182, 2007.
[30] P. Aránguiz-Urroz, J. Canales, M. Copaja et al., “Beta2-adrener-
gic receptor regulates cardiac fibroblast autophagy and collagen
degradation,” Biochimica et Biophysica Acta (BBA) - Molecular
Basis of Disease, vol. 1812, no. 1, pp. 23–31, 2011.
[31] P. Krishnamurthy, V. Subramanian, M. Singh, and K. Singh,
“β1 integrins modulate β-adrenergic receptor–stimulated
cardiac myocyte apoptosis and myocardial remodeling,”
Hypertension, vol. 49, no. 4, pp. 865–872, 2007.
[32] W. Mughal, R. Dhingra, and L. A. Kirshenbaum, “Striking a
balance: autophagy, apoptosis, and necrosis in a normal and
failing heart,” Current Hypertension Reports, vol. 14, no. 6,
pp. 540–547, 2012.
[33] B. B. Wolf and D. R. Green, “Suicidal tendencies: apoptotic cell
death by caspase family proteinases,” The Journal of Biological
Chemistry, vol. 274, no. 29, pp. 20049–20052, 1999.
[34] A. Thakur, M. J. Alam, M. R. Ajayakumar, S. Ghaskadbi,
M. Sharma, and S. K. Goswami, “Norepinephrine-induced
apoptotic and hypertrophic responses in H9c2 cardiac myo-
blasts are characterized by different repertoire of reactive oxy-
gen species generation,” Redox Biology, vol. 5, pp. 243–252,
2015.
[35] N. Saleem and S. K. Goswami, “Activation of adrenergic recep-
tor in H9c2 cardiac myoblasts co-stimulates Nox2 and the
derived ROS mediate the downstream responses,” Molecular
and Cellular Biochemistry, vol. 436, no. 1-2, pp. 167–178, 2017.
[36] M. M. Gaschler and B. R. Stockwell, “Lipid peroxidation in cell
death,” Biochemical and Biophysical Research Communica-
tions, vol. 482, no. 3, pp. 419–425, 2017.
[37] S. Choudhary, W. Zhang, F. Zhou et al., “Cellular lipid perox-
idation end-products induce apoptosis in human lens epithe-
lial cells,” Free Radical Biology & Medicine, vol. 32, no. 4,
pp. 360–369, 2002.
[38] J. Chen, L. Wang, Y. Chen, P. Sternberg, and J. Cai,
“Phosphatidylinositol 3 kinase pathway and 4-hydroxy-2-
nonenal-induced oxidative injury in the RPE,” Investigative
Ophthalmology & Visual Science, vol. 50, no. 2, pp. 936–942,
2009.
[39] M. K. Gupta, T. V. Neelakantan, M. Sanghamitra et al., “An
assessment of the role of reactive oxygen species and redox sig-
naling in norepinephrine-induced apoptosis and hypertrophy
of H9c2 cardiac myoblasts,” Antioxidants & Redox Signaling,
vol. 8, no. 5-6, pp. 1081–1093, 2006.
11Oxidative Medicine and Cellular Longevity
